[go: up one dir, main page]

AR086818A1 - CRYSTALLINE B FORM OF 2,2,2-TRIFLUORO-N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1- (3-METOXIFENIL) PROPAN-2 -IL] ACETAMIDE - Google Patents

CRYSTALLINE B FORM OF 2,2,2-TRIFLUORO-N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1- (3-METOXIFENIL) PROPAN-2 -IL] ACETAMIDE

Info

Publication number
AR086818A1
AR086818A1 ARP120102359A ARP120102359A AR086818A1 AR 086818 A1 AR086818 A1 AR 086818A1 AR P120102359 A ARP120102359 A AR P120102359A AR P120102359 A ARP120102359 A AR P120102359A AR 086818 A1 AR086818 A1 AR 086818A1
Authority
AR
Argentina
Prior art keywords
indazol
propan
trifluoro
acetamide
crystalline
Prior art date
Application number
ARP120102359A
Other languages
Spanish (es)
Inventor
Ingemo Andersson Helena
Yvonne Conway Kelly
John Quayle Michael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR086818A1 publication Critical patent/AR086818A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida, procesos para obtenerlas, intermedios farmacéuticos empleados en su elaboración, composiciones farmacéuticas que las contienen y su uso en tratamientos médicos.Crystalline forms of 2,2,2-trifluoro-N - [(1R, 2S) -1- [1- (4-fluorophenyl) indazol-5-yl] oxy-1- (3-methoxyphenyl) propan-2-yl ] acetamide, processes to obtain them, pharmaceutical intermediates used in its preparation, pharmaceutical compositions containing them and their use in medical treatments.

ARP120102359A 2011-06-29 2012-06-29 CRYSTALLINE B FORM OF 2,2,2-TRIFLUORO-N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1- (3-METOXIFENIL) PROPAN-2 -IL] ACETAMIDE AR086818A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
AR086818A1 true AR086818A1 (en) 2014-01-22

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102359A AR086818A1 (en) 2011-06-29 2012-06-29 CRYSTALLINE B FORM OF 2,2,2-TRIFLUORO-N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1- (3-METOXIFENIL) PROPAN-2 -IL] ACETAMIDE

Country Status (16)

Country Link
EP (1) EP2726464A1 (en)
JP (1) JP2014527955A (en)
KR (1) KR20140036230A (en)
CN (1) CN103814015A (en)
AR (1) AR086818A1 (en)
AU (1) AU2012277514A1 (en)
BR (1) BR112013031759A2 (en)
CA (1) CA2839398A1 (en)
IN (1) IN2014MN00023A (en)
MX (1) MX2013014566A (en)
RU (1) RU2013153466A (en)
SG (1) SG195309A1 (en)
TW (1) TW201305115A (en)
UY (1) UY34170A (en)
WO (1) WO2013001294A1 (en)
ZA (1) ZA201309480B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (en) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 Preparation method of (S) -2-chloro-1- (6-fluoro-1-chroman-2-yl) -ethanol
KR20230113770A9 (en) * 2020-11-27 2024-03-25 미라이랩 바이오사이언스 인코퍼레이티드 High purity β nicotinamide mononucleotide (NMN) and method for producing the same
CN116283781B (en) * 2022-12-16 2025-05-13 药康众拓(江苏)医药科技有限公司北京分公司 Deuterated N-phenyl indazole amide compound, pharmaceutical composition and application
KR102571432B1 (en) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 Composition for treating cancer containing indazolyl ester and amide derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
ES2535701T3 (en) 2010-07-21 2015-05-14 Astrazeneca Ab Inhaler
NZ605149A (en) 2010-07-21 2014-08-29 Astrazeneca Ab Inhaler

Also Published As

Publication number Publication date
MX2013014566A (en) 2014-09-25
CA2839398A1 (en) 2013-01-03
IN2014MN00023A (en) 2015-06-12
ZA201309480B (en) 2015-10-28
TW201305115A (en) 2013-02-01
SG195309A1 (en) 2013-12-30
JP2014527955A (en) 2014-10-23
RU2013153466A (en) 2015-08-10
AU2012277514A1 (en) 2014-01-09
BR112013031759A2 (en) 2016-12-13
KR20140036230A (en) 2014-03-25
UY34170A (en) 2013-01-31
CN103814015A (en) 2014-05-21
EP2726464A1 (en) 2014-05-07
WO2013001294A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
MX2020005645A (en) Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation.
CL2013003227A1 (en) "Substituted indazole-derived compounds, modulators of protein kinase activity; process of obtaining them; in vitro method to inhibit protein kinases; pharmaceutical composition and combination comprising them; and its use in the treatment of cancer "pct
MX379193B (en) SOLID SOLUTION COMPOSITIONS AND THEIR USE IN CHRONIC INFLAMMATION.
UY35492A (en) NEW COMPOUNDS
ECSP13012770A (en) CRYSTAL FORMS OF 5-CHLORINE-N2- (2-ISOPROPOXI-5-METHYL-4-PIPERIDIN-4-IL-PHENYL) -N4- [2- (PROPAN-2-SULPHONYL) -PENYL] -PIRIMIDIN-2,4 -DIAMINE
CL2016001120A1 (en) Compounds derived from pyrrolo1,2-f1,2,4triazine, a pharmaceutical composition that comprises them and their use in the treatment of a syncytial virus infection intermediary compounds. pct
CL2009001066A1 (en) Compounds derived from substituted carboxylic acid cyclopentane; lpa edg2 receptor inhibitors; pharmaceutical composition; preparation procedure; and use in the treatment of cardiovascular, inflammatory, metabolic, kidney, lung, oncological, immunological and allergy diseases, among others.
MX2015003140A (en) ENZALUTAMIDE FORMULATIONS.
GT201400147A (en) PYRIMIDINES AND FUSIONATED TRIAZINS REPLACED AND ITS USE
AR084691A1 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
MX2015011448A (en) COMPOUNDS AND THEIR USES TO MODULATE HEMOGLOBIN.
ECSP10010489A (en) New formulations, tablets comprising such formulations, their use and procedure for their preparation
UY33370A (en) Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures
DOP2014000133A (en) SUBSTITUTED TRIAZOLOPIRIDINS
CR20130033A (en) FORMULATIONS OF RIFAXIMINE AND USES OF THE SAME
MX351507B (en) PHARMACEUTICAL COMPOSITIONS OF CRYSTALS OF TRAMADOL AND COXIBS.
MX2013011336A (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF BENZODIAZEPINA.
ECSP13013011A (en) TRIAZOLOPIRIDINS
DOP2016000253A (en) NEW COMPOUNDS
UY32464A (en) NEW INDAZOL COMPOUNDS
UY34008A (en) ? FORMS IN SOLID STATE OF HIV INHIBITOR, PHARMACEUTICAL COMPOSITION, USE OF THE SAME, AND PROCESSES TO PREPARE SUCH FORMS ?.
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
UY32052A (en) 5-REPLACED AMINOPIRAZOLS AND USE OF THE SAME
AR086818A1 (en) CRYSTALLINE B FORM OF 2,2,2-TRIFLUORO-N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1- (3-METOXIFENIL) PROPAN-2 -IL] ACETAMIDE
CL2012000097A1 (en) Compounds derived from 3-phenoxymethylpyrrolidine, serotonin-norepinephrine reuptake inhibitors; preparation procedure; intermediate compounds; pharmaceutical composition comprising it; and its use in the treatment of pain disorders, depression, among others.

Legal Events

Date Code Title Description
FB Suspension of granting procedure